Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Morant

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Schweizerische Medizinische Wochenschrift|December 8, 1990
[BEP-chemotherapy in patients with testicular tumors--is it worthwhile?]U Hess, W F Jungi, R Morant, et al.
Radiologie (Heidelberg, Germany)|July 17, 2024
[The possible benefit of artificial intelligence in an organized population-related screening program : Initial results and perspective]R Morant, A Gräwingholt, J Subelack, et al.
Schweizerische Medizinische Wochenschrift|March 9, 1991
[Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]R Morant, B Thürlimann, W F Jungi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1992
Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancerR A Stahel, H Lacroix, J P Sculier, et al.
Cancer|May 1, 1997
A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, SwitzerlandH P Schmid, R Maibach, J Bernhard, et al.
Digestion|January 1, 1996
The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumoursB Eriksson, E T Janson, N D Bax, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG)C Sessa, J Wanders, M Roelvink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2006
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatmentA Glaus, Ch Boehme, B Thürlimann, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 24, 2010
Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCRR Morant, V Vuaroqueaux, P A Diener, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1997
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)B Thürlimann, M Castiglione, S F Hsu-Schmitz, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Schweizerische Medizinische Wochenschrift|December 8, 1990
[BEP-chemotherapy in patients with testicular tumors--is it worthwhile?]U Hess, W F Jungi, R Morant, et al.
Radiologie (Heidelberg, Germany)|July 17, 2024
[The possible benefit of artificial intelligence in an organized population-related screening program : Initial results and perspective]R Morant, A Gräwingholt, J Subelack, et al.
Schweizerische Medizinische Wochenschrift|March 9, 1991
[Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]R Morant, B Thürlimann, W F Jungi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1992
Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancerR A Stahel, H Lacroix, J P Sculier, et al.
Cancer|May 1, 1997
A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, SwitzerlandH P Schmid, R Maibach, J Bernhard, et al.
Digestion|January 1, 1996
The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumoursB Eriksson, E T Janson, N D Bax, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG)C Sessa, J Wanders, M Roelvink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2006
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatmentA Glaus, Ch Boehme, B Thürlimann, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 24, 2010
Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCRR Morant, V Vuaroqueaux, P A Diener, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1997
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)B Thürlimann, M Castiglione, S F Hsu-Schmitz, et al.
Pageof 7